EA Pharma (Eisai/Ajinomoto)
License Agreement for Elobixibat in Japan and other select countries in Asia (not China)
Collaborating selectively is an important part of our business strategy. We are especially interested in collaborating with companies with particular expertise in therapeutic areas synergistic with our science and product pipeline to realize their full potential. If you are interested in discussing how we may work together to our mutual benefit, please contact BD@albireopharma.com.